Data Analytics For Pharmaceutical Development Forum held in Amsterdam, Netherlands from 11th – 13th September is the most targeted, pharma specific platform that gives you solutions to the biggest challenges in the field of data for Pharma.
Reach new heights in precision, productivity and patient centricity by joining industry leaders from key pharma companies like Astra Zeneca, Janssen, GSK, Novartis and Merck.
Our expert panel will be sharing their insights in technical optimization; discussing tangible methods for data analysis and optimization, and translating this into real world insight for your company.
To give you a snapshot, 2018 Speakers include:
- David Whewell, Director of Architecture and Software Innovation, Merck Group
- Matt Wiener, Director, Data Science, IKU in EMEA, Celgene
- Pascal Bouquet, Global Head Technology and Architecture for Global Drug Development, Novartis
- Samiul Hasan, Director Data Curation, GSK
- Mats Sundgren, Principal Scientist, AstraZeneca
- Leonardo Rodrigues, Senior Director, AI & Machine Learning, BERG Heath
- Nigel Hughes, Scientific Director, Janssen
Artificial Intelligence, Machine Learning and other technologies are expected to make the discovery and development of new pharmaceuticals quicker, cheaper and more effective. Download this article to hear experts insights from Leonardo Rodrigues, Senior Director, AI & Machine Learning at BERG Heath about how these tools will revolutionise drug development over the next decade and what the future of a drug discovery market looks like when driven by AI.
We recently conducted a quick surveyed of the Pharma IQ community to find out how much they are investing in data analytics and why.
We discovered that nearly 50% of pharma, biotech and CRO companies don't feel that they are utilising data very efficiently within their R&D process and that all respondents are currently investing, or planning to invest in better analytics systems.
Sample attendee list for Data Analytics for Pharma R&D 2018.
While most industries are already benefiting from better use of dataanalytics, Pharma has been slow to innovate their business mode and adopt new technologies. Pharma R&D is stalling, there is a cap onproductivity and companies need to leverage data insights to move forwards. With insights from Larry Pickett, CEO, RxDataScience, this infographic provides a step-by-step guide to overcoming the key challenges faced in establishing and implementing a coherent data analytics strategy.
Data usage could lead to accelerated drug discovery, better help patients and predict emergency rush hours. To keep reading, download the PDF file.
With large scale initiatives coming into practice, such as the European Medical Information Framework (EMIF), Hughes shares his top tips for implementing a project like this. Read this interview to find out the key opportunities and threats of utilising real world data and how the rise of personalised/ precision medicine will impact the use of data.
Pharmaceutical companies have always relied on empirical data in order to identify patterns, test theories and understand the efficacy of treatments. Big data is just another evolution in a trend that has been continuing for hundreds of years: that of human beings having ever greater access to information and data. But to really garner the benefits requires a different way of looking at data. Here are 6 ways that pharmaceutical companies can use Big Data and analytics to generate business value and drive innovation.
The project in question is focused on exploiting genome sequencing efforts to discover new targets for cancer treatment. A huge opportunity for positive change. Download the Case Study to find out more.